Peptide reference
BPC-157
Body Protection Compound 157 · a synthetic pentadecapeptide
A 15-amino-acid fragment derived from a protein sequence found in human gastric juice.
Residues
15
Formula
C62H98N16O22
Molecular weight
~1419.5 g/mol
Class
Synthetic pentadecapeptide
Researched effects
Areas BPC-157 has been studied in. Every card carries an evidence-level badge.
Tendon & ligament healing
Increased fibroblast migration and F-actin formation in tendon-derived cells.
Muscle injury repair
Accelerated recovery in crush and transection injury models.
Bone healing
Improved defect healing in segmental bone models.
Gastrointestinal protection
Ulcer healing and mucosal protection; the compound derives from a gastric juice protein and is stable in gastric acid.
NSAID and alcohol lesion counteraction
Reduced GI damage from these agents in models.
Angiogenesis
New vessel formation at injury sites.
Nerve regeneration
Improved recovery in peripheral nerve and spinal injury models.
Anti-inflammatory activity
Reduced inflammatory markers in injury models.
Sequence
Fifteen residues, N-terminus to C-terminus. Hover a node to inspect; filter by class to isolate.
Hover or focus a residue to inspect.
Sequence: GEPPPGKPADDAGLV. Fifteen residues in order: Gly, Glu, Pro, Pro, Pro, Gly, Lys, Pro, Ala, Asp, Asp, Ala, Gly, Leu, Val.
Amino acid composition
How the fifteen positions distribute across eight unique residues.
Proline
Glycine
Alanine
Aspartic acid
Glutamic acid
Lysine
Leucine
Valine
Structural properties
Four readouts characterising the chain.
Readout · 01
Proline-rich
26.7% proline, including a PPP triplet at positions 3–5, which constrains backbone flexibility and confers rigidity.
Readout · 02
Net charge ≈ −2
Three acidic residues (2× Asp, 1× Glu) against one basic residue (Lys).
Readout · 03
No cysteine
No disulphide bridges, so no tertiary folding via cross-links.
Readout · 04
No aromatic residues
No Trp, Tyr or Phe, meaning negligible absorbance at 280 nm (relevant to how it's quantified analytically).
Proposed mechanisms
Pathways inferred from animal and cell studies. Proposed / preclinical — not confirmed human mechanism.
Research & regulatory status
Not an approved medicine.
BPC-157 has no marketing approval as a drug in the US, UK or EU.
US compounding restriction.
In 2023 the FDA placed BPC-157 in Category 2 of its 503A bulk drug substances review — substances with significant safety risks — meaning it should not be used in compounded preparations.
Prohibited in sport.
Listed by WADA under S0 (non-approved substances), banned at all times.
The overwhelming majority of published evidence is preclinical, from a relatively small number of research groups, and long-term human safety data is absent.